Navigation Links
FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
Date:3/3/2009

- Agency Supports Company's Production and Clinical and Preclinical Plans for DXL625 -

- Live Teleconference Scheduled with Leadership and Scientific Team for March 04, 2009 -

BRITISH COLUMBIA, Canada March 3 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

InNexus' submission included detailed information on plans for a Phase I clinical program, preclinical pharmacology and toxicology data and its current manufacturing. At the Pre-IND meeting, FDA supported InNexus' current manufacturing plans stating that the plans were suitable for the manufacture of Phase I product of DXL625 onsite at InNexus. FDA also reviewed completed animal testing and recommended a more expeditious design for the final animal studies to set the stage for human studies. Per these recommendations, InNexus foresees no regulatory impediment to the initiation of human clinical studies in early 2010.

"We are pleased to announce the completion of our pre-IND meeting with the FDA," said Dr. Jur Strobos, Vice President of Clinical & Regulatory Affairs of InNexus. "We appreciate the thorough review and clear support from FDA for our product development plan. Their review was detailed and comprehensive. As a result, we are particularly pleased that we have affirmation of a clear, simple, and rapid path for DXL625 use in human Phase I trials. Additional pre-clinical testing and analysis will be conducted over the coming months to move us along this path
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioDynamics Provides 2007 Shareholder Meeting Update
2. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
3. NxStage Medical Provides Update on Medisystems Acquisition
4. VaxGen Files 2006 Financial Statements and Provides Cash Update
5. Signalife Provides Corporate Update
6. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
7. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
8. SGX Provides Update on BCR-ABL Collaboration
9. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , Apr. 21, 2015 Research and Markets ... addition of the "Complete 2015-16 Induced Pluripotent ... their offering. Stem cell research and ... five decades, as stem cells have the unique ... their unspecialized nature allows them to differentiate into ...
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... Dr. Mark W. Sawicki , Chief ... Annual BioLogistics Summit in San Francisco, ...
(Date:4/21/2015)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced today ... results before market open on Tuesday, April 28, 2015. ... on Tuesday, April 28, 2015, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
Breaking Biology Technology:Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... Aug. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. ("MIGENIX"),announced today ... Holdings,Inc. ("DJohnson"), a significant shareholder of MIGENIX, that ... of shareholders scheduled for,October 31, 2008. As part ... of,its board of directors from seven members to ...
... CLAREMONT, Calif., Aug. 11 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... the second quarter of 2008 ended June 30 ... $1,872,647 for the second,quarter of 2007. Revenues for ... 60% from the previous year., The significant ...
... 4:30 p.m. Eastern Time -, SAN FRANCISCO, Aug. ... on its corporate progress and financial,results for the quarter ... findings of the Dimebon 12-month pivotal,trial in Alzheimer,s disease ... results from our Phase 2 study in Huntington,s disease,announced ...
Cached Biology Technology:Migenix averts proxy contest; reaches agreement with DJohnson holdings 2Migenix averts proxy contest; reaches agreement with DJohnson holdings 3Migenix averts proxy contest; reaches agreement with DJohnson holdings 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 2Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 5Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 6Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 7Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 8Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 9Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update 8
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... 2007 (Aliso Viejo, California) Ossur, an emerging leader ... a period of integration, is pleased to announce that ... of a two year cervical collar study performed by ... Tissue Interface Pressure from Four Cervical Collars, finds ...
... National Science Foundation has awarded Joan Edwards, the Washington ... professor of physics at Pomona College, a grant in ... of a high-speed imaging facility at Williams College for ... applications in the sciences. The project builds on ...
... researchers, in collaboration with the International Maize and ... research illustrates the major genetic improvements possible without ... use wild relatives of wheat as sources of ... team leader Dr Phil Larkin says. Unfortunately ...
Cached Biology News:Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2NSF awards Williams funding for high-speed imaging faciltity 2Building disease-beating wheat 2
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Human FADD Affinity Purified Polyclonal Ab...
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Biology Products: